Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard of care for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and most patients achieve tumor shrinkage (1, 2). The gene discussed is EGFR; the disease is neoplasm.